| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.058 | 0.2 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.2 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | -0.035 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | 0.064 | 0.2 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.063 | 0.2 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |